Telaglenastat

DB15232InvestigationalSmall molecule

Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

Mechanism: Pharmacologically active on Glutaminase kidney isoform, mitochondrial
Curator reviewed
Formula / weight: C₂₆H₂₄F₃N₇O₃S · 571.58 g/mol (avg)
Code names: CB-839

Resolves to

Compound

Structure

InChIKeyPRAAPINBUWJLGA-UHFFFAOYSA-NSMILESFC(F)(F)OC1=CC(CC(=O)NC2=NN=C(CCCCC3=NN=C(NC(=O)CC4=NC=CC=C4)S3)C=C2)=CC=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

25Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telaglenastat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.